Glaucoma Market – Opportunities, Key Trends, Analysis and Global Forecast to 2026

"The Latest Research Report PharmaPoint: Glaucoma - Global Drug Forecast and Market Analysis to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characterized by the loss of the retinal ganglion cells and their axons that make up the optic nerve, which results in a cupping of the optic nerve head. This leads to optic nerve damage and visual field loss. Raised intraocular pressure (IOP) is the primary risk factor for glaucoma, and progression of disease will normally stop if the IOP is lowered by 30-50%. Consequently, treatment options for glaucoma are developed around lowering the IOP. Although it is possible to slow the progression of glaucoma using current treatment options, it is not possible to reverse vision loss that has resulted from the disease.

Most drugs prescribed for glaucoma can be placed into one of four drug classes. Prostaglandin analogues (PGAs) are generally used as a first-line treatment, with beta blockers (BBs), alpha adrenergic receptor agonists (AAs), and carbonic anhydrase inhibitors (CAIs) also frequently used, albeit generally as second-line therapies in combination with PGAs. Certain combinations of available drugs are marketed as part of fixed-dose combination (FDC) therapies. Cholinergic agonists, also known as miotics, can also be used for the treatment of glaucoma, although they are much less commonly prescribed compared with PGAs, BBs, AAs, and CAIs.

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/1686306

Scope

- Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline Glaucoma market revenue from 2016-2026. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting glaucoma therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global CDI therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global glaucoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the glaucoma therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Browse Complete Report with TOC @ https://www.marketresearchreports.biz/reports/1686306/pharmapoint-glaucoma-global-drug-market-research-reports/toc

Table of Contents

1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 11

2 Executive Summary 12
2.1 Solid Growth Is Projected for the Glaucoma Market between 2016 and 2026 13
2.2 The Development of Drugs with Novel MOAs Marks a Shift in Glaucoma Corporate Strategy 15
2.3 Some Unmet Need Remains for Glaucoma, In Particular Improving Patient Compliance 16
2.4 Opportunities Remain for Products that Further Address Unmet Needs in the Glaucoma Market 17
2.5 Late-Stage Pipeline Drugs Entering the Glaucoma Market Are Poised to Drive Growth 18
2.6 What Do Physicians Think? 20

3 Introduction 22
3.1 Catalyst 22
3.2 Related Reports 23
3.3 Upcoming Related Reports 23

4 Disease Overview 24
4.1 Introduction 24
4.2 Etiology and Pathophysiology 25
4.2.1 Etiology 25
4.2.2 Pathophysiology 28
4.3 Classification 32
4.4 Symptoms 34
4.5 Prognosis and Quality of Life 35

5 Epidemiology 36
5.1 Disease Background 36
5.2 Risk Factors and Comorbidities 37
5.3 Global and Historical Trends 37
5.4 Forecast Methodology 40
5.4.1 Sources 40
5.4.2 Forecast Assumptions and Methods 44
5.4.3 Total Prevalent Cases of POAG 44
5.4.4 Total Prevalent Cases of PACG 46
5.4.5 Total Prevalent Cases of NTG and PPG 48
5.4.6 Total Prevalent Cases of SG 49
5.4.7 Diagnosed Prevalent Cases 50
5.4.8 Diagnosed Incident Cases of Acute PACG 51
5.5 Epidemiological Forecast for Glaucoma (2016-2026) 52
5.5.1 Total Prevalent Cases of POAG 52
5.5.2 Age-Specific Total Prevalent Cases of POAG 53
5.5.3 Sex-Specific Total Prevalent Cases of POAG 54
5.5.4 Diagnosed Prevalent Cases of POAG 55
5.5.5 Total Prevalent Cases of PACG 56
5.5.6 Age-Specific Total Prevalent Cases of PACG 57
5.5.7 Sex-Specific Total Prevalent Cases of PACG 58
5.5.8 Diagnosed Prevalent Cases of PACG 59
5.5.9 Total Prevalent Cases of NTG 60
5.5.10 Diagnosed Prevalent Cases of NTG 61
5.5.11 Total Prevalent Cases of PPG 62
5.5.12 Diagnosed Prevalent Cases of PPG 63
5.5.13 Total Prevalent Cases of SG 64
5.5.14 Diagnosed Prevalent Cases of SG 65
5.5.15 Diagnosed Incident Cases of Acute PACG 66
5.6 Discussion 67
5.6.1 Epidemiological Forecast Insight 67
5.6.2 Limitations of the Analysis 67
5.6.3 Strengths of the Analysis 68

6 Disease Management 69
6.1 Diagnosis Overview 69
6.2 Treatment Overview 72
6.2.1 Treatment Guidelines 74
6.2.2 Leading Prescribed Drugs 75
6.2.3 Clinical Practice 75
6.3 US 77
6.4 5EU 79
6.5 Japan 81

View Sample PDF @ https://www.marketresearchreports.biz/reports/1686306/pharmapoint-glaucoma-global-drug-market-research-reports.pdf

7 Competitive Assessment 84
7.1 Overview 84
7.2 Product Profiles - Major Brands, Prostaglandin Analogues 84
7.2.1 Xalatan (latanoprost) 85
7.2.2 Lumigan (bimatoprost) 90
7.2.3 Travatan (travoprost) 96
7.2.4 Tapros (tafluprost) 99
7.2.5 Vyzulta (latanoprostene bunod) 104
7.3 Product Profiles, Fixed-Dose Combination Therapies 110
7.3.1 Overview 110
7.3.2 Efficacy 114
7.3.3 Safety 115
7.3.4 Forecast 115
7.4 Product Profiles, Beta Blockers (numerous brands) 115
7.4.1 Overview 115
7.4.2 Efficacy 118
7.4.3 Safety 118
7.4.4 Forecast 119

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.